Press release – For immediate release
February 12, 2026 – 10:05 pm CET

Median Technologies announces collaboration with Tempus to expand access to eyonis® LCS Software as a Medical Device in the United States

The collaboration follows FDA 510(k) clearance for eyonis® LCS and aims to integrate high-performance lung cancer screening detection and diagnosis device into the clinical workflow through the Tempus Pixel platform.

Sophia Antipolis, France and Chicago, IL, USA: Median Technologies *(FR0011049824, ALMDT, "Median" or the "Company"),* developer of eyonis®, a suite of artificial intelligence (AI) powered Software as a Medical Device (SaMD) for early cancer diagnosis, and a provider of AI-enhanced and central imaging services for oncology drug developers, today announced its non-exclusive distribution agreement with Tempus AI, Inc. (NASDAQ: TEM) a technology company leading the adoption of AI to advance precision medicine.

Under the agreement, Tempus AI will distribute eyonis® LCS to U.S. imaging providers through the Tempus Pixel platform and support implementation, customer onboarding, and workflow integration. Tempus Pixel[1] is an FDA-cleared, CE-marked AI-enabled solution that offers advanced analysis, tools, and automated reporting from radiology images to help providers accurately track and quantify lesions. It aims to aid providers in making informed diagnostic and disease management decisions.

Median announced on February 9, 2026, that eyonis® LCS, its AI-based CADe/CADx Software as a Medical Device (SaMD) for lung cancer screening has received FDA 510(k) clearance. eyonis® LCS is the only device capable of detecting and characterizing lung cancer in low-dose CT scans (LDCT), with 93.3% sensitivity, 92.4% specificity, and 99.9% Negative Predictive Value (NPV) (manufacturer values calculated on a lung cancer screening reference population), helping clinicians identify suspicious findings earlier and improve the efficiency and consistency of lung cancer screening programs.

Fredrik Brag, CEO and Founder of Median Technologies stated*: "Activating our distribution collaboration with Tempus AI is a decisive step in bringing eyonis® LCS to patients at national scale. Tempus AI's strong leadership in AI-enabled precision medicine, deeply integrated data-technology ecosystem, and strong market presence make them an exceptional partner to drive rapid and high-impact adoption of eyonis® LCS across the United States."*

Razik Yousfi, Tempus SVP & GM, AI Products added*: "We believe AI reaches its full potential when it helps clinicians identify disease earlier and more accurately. By expanding our Pixel platform with sophisticated lung cancer screening AI tools, we are enabling radiologists to manage complex caseloads while prioritizing early-stage detection. Our collaboration with Median Technologies is*

[1] Tempus Pixel is manufactured and registered under Arterys Inc., a wholly owned subsidiary of Tempus, for both FDA and CE Mark purposes.

about more than technology; it's about improving the standard of care and preventing avoidable deaths through better screening access."

Revenues generated from the use of eyonis® LCS will be shared between the parties in accordance with the commercial terms of the partnership. The collaboration builds on the existing NT-APC 1508 reimbursement pathway ($601–$700) and targets the 14.5 million Americans eligible for lung cancer screening.

Median continues to progress along the European regulatory pathway for eyonis® LCS and anticipates obtaining CE marking in Q2 2026. Under the executed distribution agreement, Tempus AI would support the commercial rollout of eyonis® LCS across Europe.

Median Technologies announced the signature of the non-exclusive distribution agreement on December 8, 2025, without disclosing the partner's identity.

About Median Technologies: Pioneering innovative software as a medical device and imaging services, Median Technologies harnesses cutting-edge AI to enhance the accuracy of early cancer diagnoses and treatments. Median's offerings include iCRO, which provides medical image analysis and management in oncology trials, and eyonis®, an AI/ML tech-based suite of software as a medical device (SaMD). Median empowers biopharmaceutical entities and clinicians to advance patient care and expedite the development of novel therapies. The French-based company, with a presence in the U.S. and China, trades on the Euronext Growth market (ISIN: FR0011049824, ticker: ALMDT). Median is also eligible for the French SME equity savings plan scheme (PEA-PME). For more information, visit www.mediantechnologies.com.

Contacts

MEDIAN TECHNOLOGIES
Emmanuelle Leygues
VP, Corporate Marketing & Financial Communications
+33 6 10 93 58 88
emmanuelle.leygues@mediantechnologies.com

Investors - SEITOSEI ACTIFIN
Ghislaine Gasparetto
+33 6 85 36 76 81
ghislaine.gasparetto@seitosei-actifin.com

Press – MAARC
Bruno Arabian
+33 6 87 88 47 26
bruno.arabian@maarc.fr
Nicolas Entz
+33 6 33 67 31 54
nicolas.entz@maarc.fr

U.S. media – TODD STEIN COMMUNICATIONS
Todd Stein
+1 510.417.0612
todd@toddsteincommunications.com

Forward-Looking Statements: This press release contains forward-looking statements. These statements are not historical facts. They include projections and estimates as well as the assumptions on which these are based, statements concerning projects, objectives, intentions, and expectations with respect to future financial results, events, operations, services, product development and potential, or future performance.

These forward-looking statements can often be identified by the words "expects," "anticipates," "believes," "intends," "estimates" or "plans" and any other similar expressions. Although Median's management believes that these forward-looking statements are reasonable, investors are cautioned that forward-looking statements are subject to numerous risks and uncertainties, many of which are difficult to predict and generally beyond the

control of Median Technologies, that could cause actual results and events to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements.

All forward-looking statements in this press release are based on information available to Median Technologies as of the date of the press release. Median Technologies does not undertake to update any forward-looking information or statements, subject to applicable regulations, in particular Articles 223-1 et seq. of the General Regulation of the French Autorité des Marchés Financiers.

About Tempus: Tempus is a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare. With one of the world's largest libraries of multimodal data, and an operating system to make that data accessible and useful, Tempus provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics. The goal is for each patient to benefit from the treatment of others who came before by providing physicians with tools that learn as the company gathers more data. For more information, visit tempus.com.

Forward Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the "Securities Act"), and Section 21E of the Securities Exchange Act of 1934, as amended, about Tempus and Tempus' industry that involve substantial risks and uncertainties. All statements other than statements of historical facts contained in this press release are forward-looking statements, including, but not limited to, statements regarding the expected outcomes and potential benefits of the collaboration with Median Technologies . In some cases, you can identify forward-looking statements because they contain words such as "anticipate," "believe," "contemplate," "continue," "could," "estimate," "expect," "going to," "intend," "may," "plan," "potential," "predict," "project," "should," "target," "will," or "would" or the negative of these words or other similar terms or expressions. Tempus cautions you that the foregoing may not include all of the forward-looking statements made in this press release.

You should not rely on forward-looking statements as predictions of future events. Tempus has based the forward-looking statements contained in this press release primarily on its current expectations and projections about future events and trends that it believes may affect Tempus' business, financial condition, results of operations and prospects. These forward-looking statements are subject to risks and uncertainties related to: Tempus' financial performance; the ability to attract and retain customers and partners; managing Tempus' growth and future expenses; competition and new market entrants; compliance with new laws, regulations and executive actions, including any evolving regulations in the artificial intelligence space; the ability to maintain, protect and enhance Tempus' intellectual property; the ability to attract and retain qualified team members and key personnel; the ability to repay or refinance outstanding debt, or to access additional financing; future acquisitions, divestitures or investments; the potential adverse impact of climate change, natural disasters, health epidemics, macroeconomic conditions, and war or other armed conflict, as well as risks, uncertainties, and other factors described in the section titled "Risk Factors" in Tempus' Quarterly Report on Form 10-K for the fiscal year ended December 31, 2024 filed with the Securities and Exchange Commission ("SEC") as well as in other filings Tempus may make with the SEC in the future. In addition, any forward-looking statements contained in this press release are based on assumptions that Tempus believes to be reasonable as of this date. Tempus undertakes no obligation to update any forward-looking statements to reflect events or circumstances after the date of this press release or to reflect new information or the occurrence of unanticipated events, except as required by law.